DIA.CHEMILUX -SARS-CoV-2 Spike/RBD Ab – CLIA

The Antibody assay is intended for testing:

1. health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike/RBD antibodies.
2. normal population for epidemiology studies on presence of potential “protective” Antibodies to SARS-CoV-2 Spike/RBD;
3. PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies;
4. human donors, recovered from COVID-19 infection, positive for anti-Spike/RBD antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
5. vaccinated individuals to assure a reliable positive immunization with development of anti Spike/RBD antibodies.